Media release
From:
JAMA
Long-Term Outcomes of Medical Management vs Bariatric Surgery in Type 2 Diabetes
About The Study: After 7 to 12 years of follow-up, individuals originally randomized to undergo bariatric surgery compared with medical/lifestyle intervention had superior glycemic control with less diabetes medication use and higher rates of diabetes remission.
Organisation/s:
University of Pittsburgh, USA
Funder:
ARMMS-T2D is supported by
cooperative agreement U01 DK114156 from the
National Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK). Funding for the original
trials were as follows: STAMPEDE was supported by
an investigator-initiated grant from Ethicon
Endo-Surgery and in-kind support from LifeScan
and NIDDK grant R01 DK089547. TRIABETES was
funded by NIDDK grants RC1DK086037 and R01
DK095128, and by subsidization of the surgical
procedures byMagee-Womens Hospital of the
University of Pittsburgh Medical Center.
CROSSROADS was funded by NIDDK grant R01
DK089528, as well as by grants from the Group
Health Research Institute and Group Health
Foundation. The Shared Decision-Making aid used
in this trial was provided by the Informed Medical
Decisions Foundation. SLIMM-T2D was funded by
NIDDK grants RC1 DK086918, R56 DK095451, and
P30 DK036836; the Herbert Graetz Fund at Joslin
Diabetes Center; and Patient-Centered Outcomes
Research Institute grant CE-1304-6756. LifeScan,
a division of Johnson & Johnson, provided home
glucose-monitoring supplies; Nestle provided
Boost; and Novo Nordisk provided drug supplies during the original trial. All 4 studies above received
bridge funding from Covidien (now Medtronic) and
Ethicon in preparation for the current NIH-funded
observational follow-up and analysis.